928 1030
[36] Ingelsson E, Arnlo¨v J, Sundstro¨m J, Lind L. The validity of a diagnosis
of heart failure in a hospital discharge register. Eur J Heart Fail
2005;7:787–91
. http://dx.doi.org/10.1016/j.ejheart.2004.12.007.
[37]
Hammar N, Alfredsson L, Rose´n M, Spetz CL, Kahan T, Ysberg AS. A national record linkage to study acute myocardial infarction inci- dence and case fatality in Sweden. Int J Epidemiol 2001;30(Suppl 1):S30–4.[38]
Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy andro- gen suppression in men with advanced prostate cancer: a system- atic review and meta-analysis. Ann Intern Med 2000;132:566–77.
[39] Bhaskaran K, Rachet B, Evans S, Smeeth L. Re: Helene Hartvedt
Grytli, Morten Wang Fagerland, Sophie D. Fossa˚ , Kristin Austlid
Taske´n. Association between use of
b
-blockers and prostate cancer-
specific survival: a cohort study of 3561 prostate cancer patients
with high-risk or metastatic diseas. Eur Urol 2013;64:e86–7
. http:// dx.doi.org/10.1016/j.eururo.2013.07.004.
[40] O’Farrell S, Sandstro¨m K, Garmo H, et al. Risk of thromboembolic
disease in men with prostate cancer undergoing androgen depri-
vation therapy. BJU Int 2016;118:391–8
. http://dx.doi.org/10.1111/ bju.13360.
[41] Mellstro¨m D, Johnell O, Ljunggren O, et al. Free testosterone is an
independent predictor of BMD and prevalent fractures in elderly
men: MrOS Sweden. J Bone Miner Res 2006;21:529–35
. http://dx. doi.org/10.1359/jbmr.060110.
[42] LeBlanc ES, Nielson CM, Marshall LM, et al. The effects of serum
testosterone, estradiol, and sex hormone binding globulin levels on
fracture risk in older men. J Clin Endocrinol Metab 2009;94:3337–
46
. http://dx.doi.org/10.1210/jc.2009-0206.
[43] Novara G, Galfano A, Secco S, Ficarra V, Artibani W. Impact of
surgical and medical castration on serum testosterone level in
prostate cancer patients. Urol Int 2009;82:249–55
. http://dx.doi. org/10.1159/000209352 .E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 9 2 0 – 9 2 8
928